收藏切换
International experiences and its lessons of medical insurance drug price adjustment in case of indication expansion
收藏切换
Qingqiang LEI1, Zixuan HE1, Min HU1, 2, *, Wen CHEN1, 2
World Clinical Drug | 2022, 43(10) : 1292 - 1298
Less
收藏切换
World Clinical Drug | 2022, 43(10): 1292-1298
• Topic •
International experiences and its lessons of medical insurance drug price adjustment in case of indication expansion
Full
Qingqiang LEI1, Zixuan HE1, Min HU1, 2, *, Wen CHEN1, 2
Affiliations
  • 1.School of Public Health, Fudan University, Shanghai 200032, China
  • 2.Center for Research and Evaluation in Pharmacoeconomics, Fudan University, Shanghai 200032, China
Published: 2022-10-10 doi: 10.13683/j.wph.2022.10.010
Outline
收藏切换

Indication expansion is a common situation we ofter face in the dynamic adjustment of the national medical insurance drug list in China. This study reviewed the experiences of drug price adjustment in typical countries under the condition of indication expansion and summarized the enlightenment to China. Typical countries took variable measures to determine the drug prices after the expansion of new indications such as access after evaluations by indications based on list prices, weighted pricing method based on value and sales, volume-price drug pricing, indication-based pricing based on risk sharing agreements, and drug pricing based on evaluations in the initial access process. Different approaches have different impacts on protecting the financial risk of the medical insurance funds, encouraging research and development and innovation in the pharmaceutical industry, and ensuring the drug accessibility for the insured patients with new indications. We should clarify the main problems and challenges of medical insurance management in the current stage in China, draw on useful experiences, and improve the price adjustment strategies of medical insurance drugs in the case of indication expansion.

indication expansion  /  price adjustment  /  medical insurance access  /  international experiences
雷清强, 何紫璇, 胡敏, 陈文. 新增适应证情形下医保药品价格调整的国际经验及其启示. 世界临床药物, 2022 , 43 (10) : 1292 -1298 . DOI: 10.13683/j.wph.2022.10.010
Qingqiang LEI, Zixuan HE, Min HU, Wen CHEN. International experiences and its lessons of medical insurance drug price adjustment in case of indication expansion[J]. World Clinical Drug, 2022 , 43 (10) : 1292 -1298 . DOI: 10.13683/j.wph.2022.10.010
Year 2022 volume 43 Issue 10
13
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.10.010
  • Receive Date:2022-07-21
  • Online Date:2026-11-18
  • Published:2022-10-10
Article Data
Affiliations
History
  • Received:2022-07-21
Funding
Affiliations
    1.School of Public Health, Fudan University, Shanghai 200032, China
    2.Center for Research and Evaluation in Pharmacoeconomics, Fudan University, Shanghai 200032, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.10.010
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT